Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln

Roivant Sciences

11/08/2025 12:13

Overview

Roivant fiscal Q1 revenue declines significantly, reflecting increased R&D expenses

Company reports net loss from continuing operations of $273.9 mln

Roivant completed $1.5 bln share repurchase program, reducing shares by over 15%

Outlook

Roivant expects brepocitinib DM trial data in H2 2025

Company anticipates brepocitinib NIU trial results in H1 2027

Roivant plans new $500 mln share repurchase program

Company maintains cash runway into profitability

Result Drivers

R&D EXPENSES - Increased by $32.4 mln due to program-specific costs and personnel-related expenses, primarily driven by anti-FcRn franchise

SHARE REPURCHASE - Completed $1.5 bln share repurchase program, reducing shares by over 15%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$2.17 mln
Q1 EPS
-$0.33
Q1 Net Income
-$273.91 mln
Q1 Income From Operations
Miss
-$284.92 mln
-$255.80 mln (4 Analysts)
Q1 Operating Expenses
$287.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Roivant Sciences Ltd is $17.50, about 34.3% above its August 8 closing price of $11.49

Press Release: ID:nGNXbByr39

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)